Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.

ABSTRACT: Malignant tumors are complex structures composed of cancer cells and tumor microenvironmental cells. In this complex structure, cells cross-talk and interact, thus jointly promoting cancer development and metastasis. Recently, immunoregulatory molecule-based cancer immunotherapy has greatly improved treatment efficacy for solid cancers, thus enabling some patients to achieve persistent responses or cure. However, owing to the development of drug-resistance and the low response rate, immunotherapy against the available targets PD-1/PD-L1 or CTLA-4 has limited benefits. Although combination therapies have been proposed to enhance the response rate, severe adverse effects are observed. Thus, alternative immune checkpoints must be identified. The SIGLECs are a family of immunoregulatory recept

SUBMITTER: Yu Y 

PROVIDER: S-EPMC10246440 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature